Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | The safety and efficacy of MB-106 for the treatment of Waldenström’s macroglobulinemia

Mazyar Shadman • 29 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia CAR-T MB-106

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, shares some insights into the safety and efficacy of MB-106 for the treatment of Waldenström’s macroglobulinemia (WM), and ongoing studies evaluating this novel CAR-T construct. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mazyar Shadman

1:17
Dose reductions to manage AEs of ibrutinib treatment for CLL
Mazyar Shadman • 10 Dec 2023
1:32
CD20-targeted CAR T-Cell therapy for patients with indolent B-cell NHL
Mazyar Shadman • 10 Dec 2023
1:06
Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant
Mazyar Shadman • 10 Dec 2023
3:09
Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR
Mazyar Shadman • 10 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals